Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 154 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypertension, Neonatal Clear all
Completed Phase 2 Interventional

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

NCT04947124
View directory record Official record
Conditions
Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions
QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery

NCT00335244
View directory record Official record
Conditions
Heart Defects, Congenital, Hypertension, Pulmonary
Interventions
L-citrulline, Placebo of intravenous L-citrulline
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Jun 27, 2026, 5:05 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of FETO in CDH Phase III

NCT07187206
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Hypertension
Interventions
FETO, Fetal Endoluminal Tracheal Occlusion
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2033
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Not applicable Interventional

Endoscopic Goniotomy for Infantile Glaucoma

NCT00338533
View directory record Official record
Conditions
Glaucoma
Interventions
endoscopic goniotomy
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Week to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops

NCT01925391
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure, Anesthesia
Interventions
Tono-pen XL Applanation tonometer + Ocu-film +
Drug
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 18 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Jun 27, 2026, 5:05 AM EDT
Not listed No phase listed Observational

Glucocorticoids and Pulmonary Hypertension

NCT04499196
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Bronchopulmonary Dysplasia
Interventions
GlucoCorticoid
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 5 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Jun 27, 2026, 5:05 AM EDT
Terminated Not applicable Interventional

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

NCT03016156
View directory record Official record
Conditions
Retinoblastoma, Cataracts Infantile, Glaucoma, Congenital, Leucocoria
Interventions
CRADLE, Red reflex testing
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 7 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

NCT00626028
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Interventions
Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Jun 27, 2026, 5:05 AM EDT
Recruiting No phase listed Observational

Study of the Progression of Chronic Cardiovascular Conditions

NCT07420907
View directory record Official record
Conditions
Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease, Hypertension, Hypertension (HTN), Hypertrophic Cardiomyopathy Patients, Hypertrophic Cardiomyopathy Without Obstruction, Hypertrophic Cardiomyopathy, Obstructive, Dilated Cardiomyopathy (DCM), Dilated Cardiomyopathy, Dilated Cardiomyopathy, Familial
Interventions
Not listed
Lead sponsor
Prolaio
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 27, 2026, 5:05 AM EDT
Active, not recruiting No phase listed Observational

MIRACLE of LIFE Study

NCT06074601
View directory record Official record
Conditions
Preterm Labor, Preterm Birth, Preterm Birth Complication, Preterm Premature Rupture of Membrane, Preeclampsia, HELLP, Gestational Hypertension, Gestational Diabetes Mellitus in Pregnancy, Small for Gestational Age at Delivery, Intrauterine Growth Restriction
Interventions
Mirvie Predictive Test for Adverse Pregnancy Outcomes
Diagnostic Test
Lead sponsor
Mirvie
Industry
Eligibility
18 Years and older · Female only
Enrollment
10,000 participants
Timeline
2021 – 2025
U.S. locations
10
States / cities
San Diego, California • Orlando, Florida • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jun 27, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional Results available

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

NCT01409031
View directory record Official record
Conditions
Persistent Pulmonary Hypertension, Respiratory Failure
Interventions
Intravenous Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 72 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jun 27, 2026, 5:05 AM EDT
Terminated Not applicable Interventional Results available

Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn

NCT01088997
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome
Interventions
Milrinone Lactate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 10 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension

NCT00872170
View directory record Official record
Conditions
Thalassemia, Hypertension, Pulmonary
Interventions
Sildenafil
Drug
Lead sponsor
Carelon Research
Other
Eligibility
7 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Jun 27, 2026, 5:05 AM EDT
Completed No phase listed Observational

Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens

NCT00001161
View directory record Official record
Conditions
Aniridia, Eye Abnormality, Ocular Hypertension, Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 27, 2026, 5:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Frailty in Children With Cardiac Disease

NCT02999438
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure, Single Ventricle
Interventions
Actigraph to check activity levels at home
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension

NCT00325962
View directory record Official record
Conditions
Hypertension
Interventions
6R-BH4 (sapropterin dihydrochloride)
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Jun 27, 2026, 5:05 AM EDT
Active, not recruiting No phase listed Observational

Dilapan-S®: A Multicenter US E-registry

NCT04451109
View directory record Official record
Conditions
Post Term Pregnancy, Premature Rupture of Membrane, Fetal Growth Retardation, Oligohydramnios, Gestational Diabetes, High Blood Pressure in Pregnancy
Interventions
Dilapan-S
Device
Lead sponsor
Medicem Technology s.r.o.
Other
Eligibility
18 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

NCT01743001
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jun 27, 2026, 5:05 AM EDT
Completed No phase listed Observational

Evaluation of Patients With Known or Suspected Heart Disease

NCT00001313
View directory record Official record
Conditions
Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 27, 2026, 5:05 AM EDT
Recruiting Phase 2 Interventional

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

NCT05201144
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypertension
Interventions
Sildenafil Oral Suspension, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jun 27, 2026, 5:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jun 27, 2026, 5:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure

NCT01472692
View directory record Official record
Conditions
Prehypertension, Gout, Pulse Wave Velocity, Hypertension, 24 Hour Blood Pressure
Interventions
Febuxostat
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jun 27, 2026, 5:05 AM EDT
Recruiting Phase 4 Interventional

Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)

NCT07322133
View directory record Official record
Conditions
Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure
Interventions
Dopamine administration, Norepinephrine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 28 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 27, 2026, 5:05 AM EDT